Zanubrutinib (BRUKINSA) is included as a second-line therapy option for 
MCL in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)3

Zanubrutinib is a preferred regimen for short response duration 
(< expected median PFS) and extended response duration 
(> expected median PFS) to prior chemoimmunotherapy

Powerful Responses

84% of patients responded to BRUKINSA across both studies1

Study 206
PET-BASED
84
% ORR
59
% CR
Study 003
CT-BASED
84
% ORR
22
% CR

Median follow-up time was 18.4 months for Study 206 and 18.8 months for Study 0034

The efficacy of BRUKINSA was IRC-assessed in 2 clinical trials that included a total of 118 adult patients with MCL who received at least 1 prior therapy. Study BGB-3111-206 (Study 206): N=86, Phase 2, open-label, multicenter, single-arm trial; PET scans were required for response assessment. Study BGB-3111-AU-003 (Study 003): N=32, Phase 1/2, open-label, multicenter, single-arm trial; PET scans were not required for response assessment and the majority of patients were assessed by CT scan.

BTK=Bruton's tyrosine kinase; CI=confidence interval; CR=complete response; CT=computed tomography; IRC=independent review committee; NCCN=National Comprehensive Cancer Network; ORR=overall response rate; PET=positron emission tomography; PFS=progression-free survival.

View Efficacy Results

Complete
BTK Inhibition

Brukinsa Difference

Demonstrated
Safety Profile

Safety

Flexible
Dosing

Dosing
myBeiGene

Personalized Patient
Support Program

Patient Support